Adaptive Biotechnologies Corporation

ADPT

Equity

ISIN null / Valor 48278597

NASDAQ (2025-11-21)

USD 18.61+14.0%

Adaptive Biotechnologies Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Adaptive Biotechnologies Corporation operates at the intersection of biotechnology and computational science, focusing on harnessing the power of the adaptive immune system to develop clinical applications. The company's Immune Medicine Platform is a pioneering approach that combines proprietary chemistry, computational biology, and machine learning to decode the genetic information of a patient's immune system. By reading and interpreting the vast and complex genetic code of immune receptors, Adaptive Biotechnologies is able to generate and maintain a comprehensive database of immune receptor data. This database is dynamic, expanding with each new patient analysis, and serves as a foundational resource for the development of novel diagnostic and therapeutic tools aimed at managing and treating diseases by leveraging the body's own immune response.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Total revenue reached $58.9 million in Q2 2025, representing a 36% year-over-year increase with the MRD segment—contributing 85% of overall revenue—growing by 42% compared to Q2 2024.

Profitability and EBITDA Improvement

The MRD business achieved profitability with an Adjusted EBITDA of $1.9 million in Q2 2025. Overall, the company narrowed its net loss to $25.6 million from $46.2 million in Q2 2024, while non-GAAP Adjusted EBITDA losses improved from $21.4 million to $7.2 million.

Test Volume and Technological Advances

clonoSEQ test volumes increased by 37% to 25,321 tests, and technological integrations were strengthened with the launch of clonoSEQ integration into Flatiron’s OncoEMR platform and the implementation of NovaSeq X Plus for clinical sequencing.

Cost Management and Updated Guidance

Operating expenses were effectively managed, decreasing by 7% partly due to adjustments from prior period impairment charges. The company also raised its full year MRD revenue guidance to $190–$200 million and reduced the full year cash burn guidance to $45–$55 million, reflecting a disciplined approach to cost control and growth strategy.

Summarized from source with an LLMView Source

Key figures

326%1Y

125%3Y

-59.9%5Y

Performance

74.4%1Y

75.8%3Y

76.4%5Y

Volatility